No Data
No Data
No Data
No Data
No Data
Firebrick Pharma Launches Antiseptic Nasal Spray Into US Online Market
An antiseptic nasal spray developed by Melbourne-based Firebrick Pharma (ASX: FRE) to attack the common cold has been officially launched online for US customers.
Small CapsApr 17 09:56
Firebrick Pharma's Nasodine Nasal Spray Enters US Market
Firebrick Pharma (ASX:FRE) is launching its Nasodine nasal spray in the US Wednesday, according to a same-day Australian bourse filing. The nasal spray can now be purchased from the company's US websi
MT NewswiresApr 17 07:57
Firebrick Pharma Phase 2 Covid-19 Trial Published in Laryngoscope Journal
Firebrick Pharma's (ASX:FRE) phase 2 Covid-19 trial has been published in the Larynggoscope journal, according to a Tuesday Australian bourse filing. Price (AUD): $0.06, Change: $0.00, Percent Change:
MT NewswiresApr 4 05:04
Firebrick Pharma Gets Coverage Extension of COVID-19 Patent in US
Firebrick Pharma (ASX:FRE) received a notice of allowance of a second patent relating to COVID-19 in the US. The new patent for its Nasodine nasal spray specifically extended the patent coverage to in
MT NewswiresMar 4 10:08
Firebrick Pharma to Release Shares From Escrow; Shares Rise 4%
Firebrick Pharma (ASX:FRE) is set to release 62,732,537 shares from escrow upon their expiry date on Jan. 28, according to a Friday filing. Two directors of the pharmaceutical firm own 30,054,412 shar
MT NewswiresJan 12 09:10
Firebrick Pharma Withdraws Appeal Against Regulator's Decision Over Nasodine Nasal Spray
Firebrick Pharma (ASX:FRE) withdrew its appeal with the Administrative Appeals Tribunal against the Therapeutic Goods Administration's decision not to approve Nasodine nasal spray. The pharmaceutical
MT NewswiresDec 27, 2023 15:28
No Data
No Data